Madrigal Pharmaceuticals Lowers Price Target and Grants Employee Stock Awards

Bank of America Securities lowered its price target for Madrigal Pharmaceuticals (NASDAQ: MDGL) from $550 to $542 on June 11, 2026. Analyst Alexandria Hammond maintained a neutral rating on the stock.

The Conshohocken, Pennsylvania-based biotech company focuses on developing novel therapeutics against MASH. MASH stands for metabolic dysfunction-associated steatohepatitis – a liver disease in which fat accumulates in the liver and causes inflammation.

Employee Stock Awards Granted Under Nasdaq Rules

On June 22, 2026, Madrigal Pharmaceuticals announced that the company granted inducement awards under Nasdaq listing rule 5635(c)(4). This rule allows publicly traded companies to grant stock options or stock compensation to new employees as hiring incentives without requiring a shareholder vote. The awards are granted outside the regular equity compensation plan.

Presentation at Goldman Sachs Healthcare Conference

On June 10, 2026, Madrigal Pharmaceuticals presented at the 47th annual Goldman Sachs Global Healthcare Conference 2026. The presentation began at 11:20 a.m. Eastern Time. The company typically uses investor conferences to showcase its pipeline and commercial strategy.

Perspective for Investors

Madrigal Pharmaceuticals is among biotech companies specializing in rare metabolic diseases. MASH affects a growing share of the global population, particularly people with obesity, diabetes, or metabolic syndrome. The disease can lead to liver fibrosis, cirrhosis, and liver failure.

The neutral rating from Bank of America Securities suggests that the analysts are not issuing a strong buy or sell recommendation. The adjusted price target of $542 is approximately 1.5 percent below the previous estimate of $550.